Cantargia (CANTA) Corporate presentation summary

Strategic focus and pipeline

• Specializes in targeting IL1RAP, a co-receptor central to inflammation and cancer signaling, with a robust pipeline spanning oncology and autoimmune diseases.

• Lead asset nadunolimab targets IL1RAP and is in advanced clinical development for pancreatic ductal adenocarcinoma (PDAC), myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML).

• Next-generation programs (CANXX, CAN14, CAN10) expand into bispecific antibodies and autoimmune indications, with CAN10 partnered globally with Otsuka.

Clinical efficacy and safety

• Nadunolimab combined with chemotherapy in 1L PDAC shows a 32% response rate and median OS of 13.2 months, outperforming historical controls.

• High IL1RAP expression in tumors correlates with poor prognosis but predicts stronger benefit from nadunolimab therapy (OS 14.2 vs. 10.6 months).

• Safety profile notable for increased neutropenia with combination therapy, but lower rates of severe neuropathy compared to standard regimens.

Expansion into hematological malignancies

• IL1RAP is highly expressed in leukemic stem cells, especially in high-risk MDS and AML, correlating with disease aggressiveness and poor survival.

• Early clinical data in high-risk MDS show complete remissions in all evaluable patients in combination with azacitidine.